One catalyst at a time. Some of the magic happens before, some at the time of, some after. There's no way to tell which or in what combination. The market doesn't care when you need it to move — follow along and see how it unfolds.
Note for mobile users: This calendar is best viewed in horizontal (landscape) orientation.
Portfolio catalyst calendar
Verified events — May 2026 through 1H 2027
| Done | Date | Position | Catalyst | Impact |
|---|---|---|---|---|
| May 28, 2026 | MDNAF | Offering closes ($0.50/unit, units include warrants at $0.65) | Dilution magnitude locked in | |
| End H1 2026 (now) | TSHA | REVEAL Part A 12-month follow-up data (all 12 patients) | Durability of 100% response | |
| June 2026 | VLTLF | First ton commercial sale execution at Select Texas site | Validates commercial revenue inflection | |
| Q2 2026 | TSHA | REVEAL Pivotal dosing completion | Starts 6-month follow-up clock | |
| Q2 2026 | TSHA | ASPIRE dosing completion (3 patients age 2 to <4) | Supports broad label ≥2 years | |
| Q2 2026 | VSTM | RAMP 205 expansion cohort update (1L PDAC) | PDAC thesis validation | |
| Late Q2 2026 (June) | DFTX | EMERGE Phase 3 topline (DT120 ODT in MDD) | Biggest near-term binary | |
| Mid-2026 | DFTX | Ascend Phase 3 initiation (second MDD trial) | Expands MDD program | |
| Anytime 1H 2026 | VSTM | VS-7375 TARGET-D 101 expansion cohort data | KRAS G12D validation | |
| Early Q3 2026 | DFTX | Voyage Phase 3 topline (DT120 ODT in GAD, 214 pts) | Second DFTX Phase 3 | |
| Q3 2026 | IMMX | NEXICART-2 topline (40-pt BLA-enabling, AL amyloidosis) | BLA-enabling, first FDA tx | |
| Q3 2026 | TENX | LEVEL Phase 3 topline (230-pt PH-HFpEF, TNX-103) | $50 target trigger | |
| Late Q3 2026 | DFTX | Panorama Phase 3 topline (DT120 ODT in GAD, 200 pts) | Third DFTX Phase 3 | |
| Q3 2026 | DFTX | DT402 ASD Phase 2a initial data | Pipeline expansion validation | |
| 2H 2026 | MDNAF | MDNA11 expanded clinical data (IL-2 Superkine) | IL-2 thesis validation, M&A trigger | |
| 2H 2026 | KYTX | Phase 2 gMG longer-term follow-up data (1-year+) | Supports gMG Phase 3 thesis | |
| 2H 2026 | IMMX | BLA submission for NXC-201 (after topline) | Approval countdown begins | |
| 2H 2026 | CNVIF | US commercial launch (HiLight intravascular imaging) | Revenue ramp + M&A visibility | |
| 2H 2026 | LUCD | Medicare LCD decision (timing TBD) | 2-3x stock catalyst per thesis | |
| Late 2026 | VLTLF | Strategic JV updates and formal NASDAQ uplisting targets | Uplisting visibility and institutional access | |
| Sept 30, 2026 | GLSI | Insider lock-up expiration (leak-out plan begins) | Share dynamics shift | |
| Q4 2026 | KYTX | SPS BLA rolling submission completion | Priority Review countdown | |
| Q4 2026 | TSHA | PPQ manufacturing campaign completion | BLA-enabling milestone | |
| Q4 2026 / Q1 2027 | TSHA | REVEAL 6-month Pivotal interim (BLA-supporting) | Big TSHA binary | |
| Q4 2026 / Q1 2027 | GLSI | 14-event interim analysis (FLAMINGO-01) | Biggest portfolio catalyst | |
| Q1 2027 | TSHA | BLA submission (post 6-month interim) | FDA review begins | |
| Q1 2027 | DFTX | NDA submission for DT120 ODT (assuming positive Phase 3s) | Commercial pathway opens | |
| Q1 / Q2 2027 | KYTX | Potential SPS approval (Priority Review timeline) | Commercial revenue begins | |
| Q1 / Q2 2027 | IMMX | FDA action / Priority Review on NXC-201 BLA | Pre-approval re-rate | |
| 1H 2027 | VSTM | VS-7375 registrational Phase 2 initiation (PDAC, NSCLC, CRC) | Locks registrational path | |
| Mid-2027 | VSTM | RAMP 301 Phase 3 topline (recurrent LGSOC) | Major VSTM binary | |
| Ongoing | HROW | Quarterly commercial revenue + M&A optionality | Tripling thesis progression | |
| Ongoing | VSTM | AVMAPKI FAKZYNJA commercial sales (LGSOC) | 50%+ QoQ growth confirmed | |
| Ongoing | GLSI | Event accumulation updates (toward 14 events) | Triggers interim analysis |
Highlighted rows = top portfolio-impact catalysts
Compiled May 18, 2026 — verified against company SEC filings